12 Month Price Forecast For IXHL
Distance to IXHL Price Forecasts
IXHL Price Momentum
๐ค Considering Incannex (IXHL)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 8, 2025 3:50 AM UTC
IXHL Analyst Ratings & Price Targets
Currently, there are no Wall Street analyst price targets or forecasts available for IXHL (Incannex).
IXHL is currently trading at $2.10. Without active analyst coverage, investors should conduct thorough independent research and consider multiple data points beyond price targets when evaluating this stock for their portfolio.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IXHL Analyst Consensus
IXHL Price Target Range
Latest IXHL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IXHL.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Dec 8, 2022 | Mizuho | Neutral | Maintains | $0.00 | |
Nov 16, 2022 | Keybanc | Sector Weight | Downgrade | $0.00 | |
Nov 3, 2022 | Mizuho | Neutral | Downgrade | $0.00 | |
Nov 3, 2022 | Truist Securities | Hold | Downgrade | $0.00 | |
Nov 3, 2022 | Raymond James | Outperform | Maintains | $0.00 | |
Nov 3, 2022 | RBC Capital | Outperform | Maintains | $0.00 | |
Nov 3, 2022 | Barclays | Overweight | Maintains | $0.00 | |
Oct 24, 2022 | Morgan Stanley | Equal-Weight | Maintains | $0.00 | |
Oct 24, 2022 | Truist Securities | Buy | Maintains | $0.00 | |
Oct 24, 2022 | Keybanc | Overweight | Maintains | $0.00 | |
Oct 24, 2022 | RBC Capital | Outperform | Maintains | $0.00 | |
Oct 21, 2022 | Needham | Hold | Downgrade | $0.00 | |
Oct 17, 2022 | Mizuho | Buy | Maintains | $0.00 | |
Oct 11, 2022 | Canaccord Genuity | Buy | Initiates | $0.00 | |
Sep 23, 2022 | BTIG | Neutral | Initiates | $0.00 | |
Aug 4, 2022 | Mizuho | Buy | Maintains | $0.00 | |
Aug 4, 2022 | Morgan Stanley | Equal-Weight | Maintains | $0.00 | |
Aug 4, 2022 | Raymond James | Outperform | Maintains | $0.00 | |
Aug 4, 2022 | Needham | Buy | Maintains | $0.00 | |
Aug 1, 2022 | RBC Capital | Outperform | Maintains | $0.00 |
Stocks Similar to Incannex Healthcare Limited
The following stocks are similar to Incannex based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Incannex Healthcare Limited (IXHL) Financial Data
Incannex Healthcare Limited has a market capitalization of $38.81M with a P/E ratio of -1.9x. The company generates $12,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +516.7% quarter-over-quarter, while maintaining an operating margin of -53,833.3% and return on equity of -115.2%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Incannex Healthcare Limited (IXHL) Company Overview
About Incannex Healthcare Limited
Develops psychedelic medicines for chronic diseases.
The company operates as a clinical-stage biopharmaceutical firm, focusing on the research, development, manufacture, sale, and distribution of innovative psychedelic therapies. It generates revenue through clinical trials and potential commercialization of its drug candidates, including IHL-42X and PSX-001, targeting various chronic conditions.
Incannex Healthcare is headquartered in Sydney, Australia, and is actively pursuing multiple clinical trials to expand its portfolio of treatments for diseases such as obstructive sleep apnea, generalized anxiety disorder, rheumatoid arthritis, and other inflammatory conditions.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
9
CEO
Mr. Joel Bradley Latham
Country
Australia
IPO Year
2022
Website
www.incannex.comIncannex Healthcare Limited (IXHL) Latest News & Analysis
Dr. Wimms has joined the team, bringing significant experience in industry and clinical development focused on sleep medicine innovation.
Dr. Wimms' expertise in sleep medicine could indicate potential advancements or new products, impacting company performance and stock value in the healthcare sector.
Incannex Healthcare Inc. (Nasdaq: IXHL) reported positive topline results from a pharmacokinetics and safety study of IHL-42X, a novel treatment for Obstructive Sleep Apnea.
Positive results from Incannex's IHL-42X study could boost investor confidence, indicating potential for market approval and revenue growth in a lucrative therapeutic area.
Incannex Healthcare Inc. (NASDAQ: IXHL) reported 1Q 2025 R&D costs of $2.9M, a $0.3M increase from 1Q 2024, according to Stonegate Capital Partners' updated coverage.
Increased R&D costs may indicate a focus on innovation, potentially impacting future growth and profitability for Incannex Healthcare Inc. Shareholder sentiment could be affected.
Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates
2 months agoIncannex Healthcare Inc. (Nasdaq: IXHL) reported its fiscal Q1 results for the quarter ending September 30, 2024, highlighting its focus on innovative medicines for chronic diseases.
Incannex's fiscal first quarter results can indicate its financial health and progress in drug development, affecting investor sentiment and potential stock performance.
Incannex Healthcare Inc. appointed Dr. Lou Barbato as Chief Medical Officer. He has extensive drug development experience and will support the company's clinical programs in several chronic diseases.
The appointment of an experienced CMO signals potential advancement in drug development, which could enhance Incannex's clinical programs and attract investor confidence.
Stonegate Capital Partners initiates coverage on Incannex Healthcare Inc. (NASDAQ: IXHL), which is advancing cannabinoid and psychedelic therapeutics and conducting an FDA trial for Obstructive Sleep Apnea. Top-line data expected in H1 2025.
Stonegate Capital Partners' coverage initiation on Incannex Healthcare highlights potential growth from its innovative cannabinoid therapies and upcoming clinical trial results, impacting investor sentiment.
Frequently Asked Questions About IXHL Stock
What is Incannex Healthcare Limited's (IXHL) stock forecast for 2025?
Analyst forecasts for Incannex Healthcare Limited (IXHL) are not currently available. The stock is trading at $2.10.
Is IXHL stock a good investment in 2025?
Analyst ratings for IXHL are not currently available. The stock is currently trading at $2.10. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for IXHL stock?
Price predictions from Wall Street analysts for IXHL are not currently available. The stock is trading at $2.10.
What is Incannex Healthcare Limited's business model?
The company operates as a clinical-stage biopharmaceutical firm, focusing on the research, development, manufacture, sale, and distribution of innovative psychedelic therapies. It generates revenue through clinical trials and potential commercialization of its drug candidates, including IHL-42X and PSX-001, targeting various chronic conditions.
What is the highest forecasted price for IXHL Incannex Healthcare Limited?
Price targets from Wall Street analysts for IXHL are not currently available. The stock is trading at $2.10.
What is the lowest forecasted price for IXHL Incannex Healthcare Limited?
Price targets from Wall Street analysts for IXHL are not currently available. The stock is trading at $2.10.
What is the overall IXHL consensus from analysts for Incannex Healthcare Limited?
Analyst ratings for IXHL are not currently available. The stock is trading at $2.10.
How accurate are IXHL stock price projections?
Stock price projections, including those for Incannex Healthcare Limited, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.